We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020.
- Authors
Dannehl, Dominik; von Au, Alexandra; Engler, Tobias; Volmer, Léa Louise; Gutsfeld, Raphael; Englisch, Johannes Felix; Hahn, Markus; Hawighorst-Knapstein, Sabine; Chaudhuri, Ariane; Bauer, Armin; Wallwiener, Markus; Taran, Florin-Andrei; Wallwiener, Diethelm; Brucker, Sara Yvonne; Wallwiener, Stephanie; Hartkopf, Andreas Daniel; Dijkstra, Tjeerd Maarten Hein
- Abstract
Simple Summary: This research analyzed health data from 27,869 female breast cancer patients and 55,738 controls in Germany to develop a breast cancer disease model, focusing on stages and tumor subtypes from 2010 to 2020. It found that the majority of patients had HR+ tumors, with HR+/HER2− being the most common subtype. The study revealed significant survival differences across stages and subtypes, with stages B and C showing much lower survival rates than early-stage or control groups. It also noted worse outcomes for the HR−/HER2− subtype. This is the first study of its kind to utilize German claims data to model breast cancer, offering crucial insights into the disease's real-world epidemiology and treatment outcomes. Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer). Tumor subtypes were estimated based on the prescription of antihormonal or HER2-targeted therapy. The study established that 77.9% of patients had HR+ breast cancer and 9.8% HER2+; HR+/HER2− was the most common subtype (70.9%). Overall survival (OS) analysis demonstrated significantly lower survival rates for stages B and C than for controls, with 5-year OS rates ranging from 79.3% for stage B to 35.4% for stage C. OS rates were further stratified by tumor subtype and stage, revealing varying prognoses. Distant recurrence-free survival (DRFS) analysis showed higher recurrence rates in stage B than in stage A, with HR−/HER2− displaying the worst DRFS. This study, the first to model breast cancer subtypes, stages, and outcomes using German claims data, provides valuable insights into real-world breast cancer epidemiology and demonstrates that this breast cancer disease model has the potential to be representative of treatment outcomes.
- Subjects
GERMANY; LYMPH nodes; HUMAN services programs; DATA analysis; SURVIVAL rate; MEDICAL prescriptions; RESEARCH funding; BREAST tumors; RETROSPECTIVE studies; TREATMENT effectiveness; DESCRIPTIVE statistics; PROGNOSIS; INSURANCE companies; OVERALL survival
- Publication
Cancers, 2024, Vol 16, Issue 8, p1490
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16081490